Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer.
Tongchen HeCaleb ChengYuanyuan QiaoHanbyul ChoEleanor YoungRahul MannanSomnath MahapatraStephanie J MinerYang ZhengNamHoon KimVictoria Z ZengJasmine P WisniewskiSiyu HouBailey JacksonXuhong CaoFengyun SuRui WangYu ChangBilash KuilaSubhendu MukherjeeSandeep DukareKiran B AithalSamiulla D SChandrasekhar AbbineniCostas Andreas LyssiotisAbhijit ParoliaLanbo XiaoArul M ChinnaiyanPublished in: bioRxiv : the preprint server for biology (2024)
models. Additionally, our study describes two distinct mechanisms of resistance to PROTAC degraders, providing crucial insights into potential challenges facing their clinical application. These findings are critical for advancing PROTAC-based therapies to clinical settings as targeted therapies for cancers.